123rf.com/valentinakruThe aim of this unique initiative, part of the so-called Generation Study, is to sequence the genomes of 100,000 newborns in England to enable the early detection of over 200 selected conditions and to accelerate the treatment of rare diseases.
IPS-Integrated Project Services, LLC / WuXi BiologicsWuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global sites.
Orbis MedicinesOrbis Medicines secures €90m in Series A funding to accelerate the development of oral macrocycle drugs, leveraging automated chemistry and machine learning.
pixabay.com - geraltThank you for a successful 2024!
SK BioscienceIn parallel with the expansion of its collaboration with SK Bioscience Co. Ltd, the French pharmaceutical company Sanofi SA has announced Phase III testing of its licensed pneumococcal conjugate vaccine PCV21.
wikioedia.org - Von http://web2.airmail.net/uthman/specimens/index.html, Gemeinfrei, https://commons.wikimedia.org/w/index.php?curid=841015Screening a library of 712 market-approved drugs, German researchers have found that a cough medicine most efficiently reduced incurable lung fibrosis in mice and in vitro.
Photys TherapeuticsNovo Nordiks has licenced Photys Therapeutics PHICS platform to target a single cardiometabolic target. Photys got US$186m upfront.
DeepLife SASGenerative AI specialist DeepLife SAS has raises US$10m in a Series A financing led by YZR Capital and Relyens Innovation Santé with participation from Beiersdorf Venture Capital, Prunay Group, and existing investors.
Wilfried Le Goff (INSERM, Sorbonne Université)Researchers at Sorbonne Paris have discovered that a membrane protein in adipocytes of obese mice and humans changes the lipid composition of adipose tissue macrophages rendering them more inflammatory and reducing insulin resistance.
Synaffix/LanzaElevation Oncology Inc has inked a US$368m license agreement with Lonza subsidiary Synaffix BV under which Synaffix will link Elevation’s HER3 antibody seribantumab to a monomethyl auristatin E (MMAE) toxic payload with broad therapeutic index.